相似文献
1
Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia.
Haematologica. 2016 Jan;101(1):e8-e11. doi: 10.3324/haematol.2015.133348. Epub 2015 Sep 24.
2
Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia.
Am J Hematol. 2015 Apr;90(4):310-3. doi: 10.1002/ajh.23934.
3
SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia.
Br J Haematol. 2021 Jul;194(1):200-210. doi: 10.1111/bjh.17428. Epub 2021 May 4.
4
Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity.
Blood. 2020 Oct 22;136(17):1968-1979. doi: 10.1182/blood.2019004719.
5
Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia.
Blood. 2012 May 24;119(21):5021-9. doi: 10.1182/blood-2012-01-401885. Epub 2012 Apr 6.
6
An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.
Blood. 2013 Feb 14;121(7):1200-8. doi: 10.1182/blood-2012-09-453977. Epub 2012 Dec 6.
7
Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model.
Am J Hematol. 2021 Feb 1;96(2):251-257. doi: 10.1002/ajh.26048. Epub 2020 Nov 27.
8
RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of β-thalassemia intermedia.
Am J Hematol. 2018 Jun;93(6):745-750. doi: 10.1002/ajh.25079. Epub 2018 Mar 23.
9
Exogenous iron increases hemoglobin in beta-thalassemic mice.
Exp Hematol. 2009 Feb;37(2):172-83. doi: 10.1016/j.exphem.2008.10.004. Epub 2008 Dec 6.
10
The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia.
Int J Mol Sci. 2021 Jan 16;22(2):873. doi: 10.3390/ijms22020873.
引用本文的文献
1
Current Landscape of Hepcidin Therapeutics.
Adv Exp Med Biol. 2025;1480:399-418. doi: 10.1007/978-3-031-92033-2_26.
2
A TMPRSS6-inhibiting mAb improves disease in a β-thalassemia mouse model and reduces iron in healthy humans.
JCI Insight. 2025 Jun 23;10(12). doi: 10.1172/jci.insight.191813.
3
Rational Design of Selective TMPRSS6 Peptidomimetic Inhibitors via Exploitation of the S2 Subpocket.
J Med Chem. 2024 Aug 8;67(15):12969-12983. doi: 10.1021/acs.jmedchem.4c00922. Epub 2024 Jul 19.
4
Combination of a TGF-β ligand trap (RAP-GRL) and TMPRSS6-ASO is superior for correcting β-thalassemia.
Am J Hematol. 2024 Jul;99(7):1300-1312. doi: 10.1002/ajh.27332. Epub 2024 Apr 25.
5
A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice.
Blood Adv. 2024 Apr 23;8(8):1898-1907. doi: 10.1182/bloodadvances.2023012010.
6
Iron chelation improves ineffective erythropoiesis and iron overload in myelodysplastic syndrome mice.
Elife. 2023 Dec 28;12:e83103. doi: 10.7554/eLife.83103.
7
Normal and dysregulated crosstalk between iron metabolism and erythropoiesis.
Elife. 2023 Aug 14;12:e90189. doi: 10.7554/eLife.90189.
8
Thalassemia and Nanotheragnostics: Advanced Approaches for Diagnosis and Treatment.
Biosensors (Basel). 2023 Apr 1;13(4):450. doi: 10.3390/bios13040450.
9
Mitapivat, a pyruvate kinase activator, improves transfusion burden and reduces iron overload in β-thalassemic mice.
Haematologica. 2023 Sep 1;108(9):2535-2541. doi: 10.3324/haematol.2022.282614.
10
Rise of the planet of rare anemias: An update on emerging treatment strategies.
Front Med (Lausanne). 2023 Jan 9;9:1097426. doi: 10.3389/fmed.2022.1097426. eCollection 2022.
本文引用的文献
1
β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies.
Haematologica. 2015 Apr;100(4):418-30. doi: 10.3324/haematol.2014.114827.
2
Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia.
Am J Hematol. 2015 Apr;90(4):310-3. doi: 10.1002/ajh.23934.
3
Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice.
J Clin Invest. 2013 Apr;123(4):1531-41. doi: 10.1172/JCI66969. Epub 2013 Mar 25.
4
An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.
Blood. 2013 Feb 14;121(7):1200-8. doi: 10.1182/blood-2012-09-453977. Epub 2012 Dec 6.
5
The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia.
Blood Rev. 2012 Apr;26 Suppl 1(0 1):S12-5. doi: 10.1016/S0268-960X(12)70005-X.
6
Decreased hepcidin expression in murine β-thalassemia is associated with suppression of Bmp/Smad signaling.
Blood. 2012 Mar 29;119(13):3187-9. doi: 10.1182/blood-2012-01-405563.
7
β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.
Blood. 2011 Oct 20;118(16):4321-30. doi: 10.1182/blood-2011-03-283614. Epub 2011 Jul 18.
8
Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia.
Blood. 2008 Aug 1;112(3):875-85. doi: 10.1182/blood-2007-12-126938. Epub 2008 May 14.
9
Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications.
Blood. 2008 Feb 1;111(3):1690-9. doi: 10.1182/blood-2007-07-102335. Epub 2007 Nov 1.
10
Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin.
Blood. 2007 Jun 1;109(11):5027-35. doi: 10.1182/blood-2006-09-048868. Epub 2007 Feb 13.
Zotero 插件